Visión generalGráficoNoticiasTraderScreen

HSBC Call 52 BAYN 13.12.2028/  DE000HS57EZ1  /

Frankfurt Zert./HSBC
15/11/2024  21:35:34 Diferencia-0.007 Bid21:52:36 Ask21:52:36 Subyacente Precio de ejercicio Fecha de expiración Tipo de opción
0.166EUR -4.05% 0.167
Volumen de oferta: 20,000		 0.210
Tamaño/ Volumen/ Formato de Ask: 20,000		 BAYER AG NA O.N. 52.00 EUR 13/12/2028 Call
TeleTrader 12/11 Bayer dips 12%, hits 20-year low after earnings report
TeleTrader 12/11 Bayer's sales in Q3 down 3.6% to €9.9 billion
TeleTrader 16/08 Bayer jumps 10% after Roundup court win
GlobeNewswire 02/08 Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire 11/07 AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire 25/06 AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
GlobeNewswire 30/05 Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire 30/05 BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 28/05 Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
TeleTrader 14/05 Bayer's sales in Q1 at €13.7 billion, down 4.3%
GlobeNewswire 02/05 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire 18/04 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire 16/04 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire 11/04 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire 09/04 AskBio Names Mansuo Shannon Chief Scientific Officer
GlobeNewswire 25/03 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire 14/03 Bayer and Aignostics to collaborate on next generation precision oncology
GlobeNewswire 06/03 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
TeleTrader 05/03 Bayer's Q4 sales at €11.9 billion
GlobeNewswire 04/03 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
TeleTrader 04/03 Earnings preview: Bayer, Broadcom among those in calendar
GlobeNewswire 15/02 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire 13/02 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire 13/02 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure